Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Incyte will present four rapid oral presentations of new oncology data at the ESMO Congress 2026 in Madrid, October 23-27. Featured assets include KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890, both in ongoing Phase 3 programs, plus CDK2 inhibitor INCB123667 in ovarian cancer. Incyte will host an investor event and webcast on October 26, 2026, at 2:30 p.m.
Key figures
- Investor event
- Monday, October 26, 2026, 2:30-4:00 p.m. ET
- Rapid oral presentations
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.